Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
15, 2025 Tripling the standard dose of semaglutide, a popular drug prescribed to treat obesity, led to significantly greater weight loss and associated metabolic benefits without increased risk of serious side effects, a multicenter clinical trial led by a UT Southwestern Medical Center researcher shows
MC3R and MC5R activity has been investigated in the context of metabolic regulation and exocrine gland function respectively
Prior to that, the company had committed $500M into an active pharmaceutical ingredient (API) plant in Ireland, $1.6B to expand its new manufacturing sites in Indiana, and $1.7B over three years for the expansion of their fill-finish sites at Research Triangle Park, NC and Concord, NC
How Clinicians Can Stay Involved With the rise of telehealth-driven GLP-1 treatment, clinicians must find ways to remain central to patient care
